Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.

Banerjee A, Birts CN, Darley M, Parker R, Mirnezami AH, West J, Cutress RI, Beers SA, Rose-Zerilli MJJ, Blaydes JP.

Carcinogenesis. 2019 Jul 20;40(7):871-882. doi: 10.1093/carcin/bgy174.

PMID:
30668646
2.

Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.

Sreekumar R, Harris S, Moutasim K, DeMateos R, Patel A, Emo K, White S, Yagci T, Tulchinsky E, Thomas G, Primrose JN, Sayan AE, Mirnezami AH.

JAMA Netw Open. 2018 Oct 5;1(6):e183115. doi: 10.1001/jamanetworkopen.2018.3115.

3.

Bilateral versus unilateral botulinum toxin injections for chronic anal fissure: a randomised trial.

Pilkington SA, Bhome R, Welch RE, Ku F, Warden C, Harris S, Hicks J, Richardson C, Dudding TC, Knight JS, King AT, Mirnezami AH, Beck NE, Nichols PH, Nugent KP.

Tech Coloproctol. 2018 Jul;22(7):545-551. doi: 10.1007/s10151-018-1821-2. Epub 2018 Jul 18.

4.

The Colorectal Cancer Microenvironment: Strategies for Studying the Role of Cancer-Associated Fibroblasts.

Bhome R, Mellone M, Emo K, Thomas GJ, Sayan AE, Mirnezami AH.

Methods Mol Biol. 2018;1765:87-98. doi: 10.1007/978-1-4939-7765-9_6.

5.

Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer.

Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE, Mirnezami AH.

Cancer Lett. 2018 Apr 28;420:228-235. doi: 10.1016/j.canlet.2018.02.002. Epub 2018 Feb 7. Review.

6.

Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.

Bhome R, Goh RW, Bullock MD, Pillar N, Thirdborough SM, Mellone M, Mirnezami R, Galea D, Veselkov K, Gu Q, Underwood TJ, Primrose JN, De Wever O, Shomron N, Sayan AE, Mirnezami AH.

Aging (Albany NY). 2017 Dec 28;9(12):2666-2694. doi: 10.18632/aging.101355.

7.

Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.

Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M, Noble F, Moutasim KA, King EV, Vijayanand P, Mirnezami AH, Underwood TJ, Ottensmeier CH, Thomas GJ.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx121.

8.

Pelvic exenteration with en bloc resection of the pelvic sidewall and intraoperative electron beam radiotherapy with Mobetron® for locally advanced rectal cancer.

Rangarajan K, Bhome R, Bateman N, Naga A, Simon M, Donovan K, Smith J, Mirnezami AH.

Tech Coloproctol. 2017 Jun;21(6):493-495. doi: 10.1007/s10151-017-1649-1. Epub 2017 Jun 14. No abstract available.

9.

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer.

West MA, Roman A, Sayan E, Primrose JN, Wedge SR, Underwood TJ, Mirnezami AH.

Crit Rev Oncol Hematol. 2017 Apr;112:80-102. doi: 10.1016/j.critrevonc.2017.02.008. Epub 2017 Feb 16. Review.

PMID:
28325268
10.

Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.

Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH.

New Horiz Transl Med. 2016 Jan;3(1):9-21.

11.

A top-down view of the tumor microenvironment: structure, cells and signaling.

Bhome R, Bullock MD, Al Saihati HA, Goh RW, Primrose JN, Sayan AE, Mirnezami AH.

Front Cell Dev Biol. 2015 May 29;3:33. doi: 10.3389/fcell.2015.00033. eCollection 2015. Review.

12.

miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.

Cellura D, Pickard K, Quaratino S, Parker H, Strefford JC, Thomas GJ, Mitter R, Mirnezami AH, Peake NJ.

Mol Cancer Res. 2015 Jul;13(7):1095-1105. doi: 10.1158/1541-7786.MCR-14-0466. Epub 2015 May 1.

13.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH.

Oncotarget. 2015 Mar 30;6(9):7262-79.

14.

Systematic review of emergent laparoscopic colorectal surgery for benign and malignant disease.

Chand M, Siddiqui MR, Gupta A, Rasheed S, Tekkis P, Parvaiz A, Mirnezami AH, Qureshi T.

World J Gastroenterol. 2014 Dec 7;20(45):16956-63. doi: 10.3748/wjg.v20.i45.16956.

15.

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.

Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH.

World J Gastroenterol. 2014 Oct 14;20(38):14018-32. doi: 10.3748/wjg.v20.i38.14018. Review.

16.

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.

Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH.

Br J Cancer. 2014 Oct 14;111(8):1500-8. doi: 10.1038/bjc.2014.419. Epub 2014 Sep 16.

17.

Molecular profiling of the invasive tumor microenvironment in a 3-dimensional model of colorectal cancer cells and ex vivo fibroblasts.

Bullock MD, Mellone M, Pickard KM, Sayan AE, Mitter R, Primrose JN, Packham GK, Thomas G, Mirnezami AH.

J Vis Exp. 2014 Apr 29;(86). doi: 10.3791/51475.

18.

miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH.

Cancer Res. 2013 Nov 1;73(21):6435-47. doi: 10.1158/0008-5472.CAN-12-3308. Epub 2013 Aug 15.

19.

FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role.

Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, Primrose JN, Ottensmeier C, Packham GK, Thomas G, Mirnezami AH.

Br J Cancer. 2013 Jul 23;109(2):387-94. doi: 10.1038/bjc.2013.355. Epub 2013 Jul 4.

20.

Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.

Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, Mitter R, Primrose JN, Thomas GJ, Packham GK, Mirnezami AH.

Cell Death Dis. 2013 Jun 20;4:e684. doi: 10.1038/cddis.2013.213. Erratum in: Cell Death Dis. 2013;4:e748. Mirenzami, AH [corrected to Mirnezami, AH].

21.

Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications.

Mirnezami R, Chang GJ, Das P, Chandrakumaran K, Tekkis P, Darzi A, Mirnezami AH.

Surg Oncol. 2013 Mar;22(1):22-35. doi: 10.1016/j.suronc.2012.11.001. Epub 2012 Dec 25. Review.

22.

A prospective case-control study of extralevator abdominoperineal excision (ELAPE) of the rectum versus conventional laparoscopic and open abdominoperineal excision: comparative analysis of short-term outcomes and quality of life.

Vaughan-Shaw PG, Cheung T, Knight JS, Nichols PH, Pilkington SA, Mirnezami AH.

Tech Coloproctol. 2012 Oct;16(5):355-62. doi: 10.1007/s10151-012-0851-4. Epub 2012 Jul 10.

PMID:
22777690
23.

The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.

Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH.

Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Review.

PMID:
22721580
24.

MicroRNA Control of Invasion and Metastasis Pathways.

Sreekumar R, Sayan BS, Mirnezami AH, Sayan AE.

Front Genet. 2011 Sep 5;2:58. doi: 10.3389/fgene.2011.00058. eCollection 2011.

25.

MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression.

Bullock MD, Sayan AE, Packham GK, Mirnezami AH.

Biol Cell. 2012 Jan;104(1):3-12. doi: 10.1111/boc.201100115. Epub 2011 Dec 9. Review.

PMID:
22188537
26.

Acute radiation enteritis causing small bowel obstruction.

Curtis NJ, Bryant T, Raj S, Bateman AR, Mirnezami AH.

Ann R Coll Surg Engl. 2011 Oct;93(7):e129-30. doi: 10.1308/10.1308/147870811X602122.

27.

Early experience with laparoscopic extralevator abdominoperineal excision within an enhanced recovery setting: analysis of short-term outcomes and quality of life.

Vaughan-Shaw PG, King AT, Cheung T, Beck NE, Knight JS, Nichols PH, Nugent KP, Pilkington SA, Smallwood JA, Mirnezami AH.

Ann R Coll Surg Engl. 2011 Sep;93(6):451-9. doi: 10.1308/003588411X588621.

28.

Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis.

Mirnezami R, Mirnezami AH, Chandrakumaran K, Abu Hilal M, Pearce NW, Primrose JN, Sutcliffe RP.

HPB (Oxford). 2011 May;13(5):295-308. doi: 10.1111/j.1477-2574.2011.00295.x. Epub 2011 Mar 2. Review.

29.

Clinical algorithms for the surgical management of locally recurrent rectal cancer.

Mirnezami AH, Sagar PM, Kavanagh D, Witherspoon P, Lee P, Winter D.

Dis Colon Rectum. 2010 Sep;53(9):1248-57. doi: 10.1007/DCR.0b013e3181e10b0e. Review.

PMID:
20706067
30.

Surgery for recurrent rectal cancer: technical notes and management of complications.

Mirnezami AH, Sagar PM.

Tech Coloproctol. 2010 Sep;14(3):209-16. doi: 10.1007/s10151-010-0585-0. Epub 2010 May 12. Review.

PMID:
20461538
31.

Sugarbaker procedure for pseudomyxoma peritonei.

Mirnezami AH, Moran BJ, Cecil TD.

Tech Coloproctol. 2009 Dec;13(4):373-4. doi: 10.1007/s10151-009-0513-3. No abstract available.

PMID:
19690800
32.

Ileal pouch-vaginal fistula: treatment with the new Surgisis Biodesign fistula plug.

Mirnezami AH, Gonsalves S, Gatt M, Sagar PM.

Tech Coloproctol. 2009 Sep;13(3):259-60. doi: 10.1007/s10151-009-0516-0. No abstract available.

PMID:
19629379
33.

Robotic colorectal surgery: hype or new hope? A systematic review of robotics in colorectal surgery.

Mirnezami AH, Mirnezami R, Venkatasubramaniam AK, Chandrakumaran K, Cecil TD, Moran BJ.

Colorectal Dis. 2010 Nov;12(11):1084-93. doi: 10.1111/j.1463-1318.2009.01999.x. Review.

PMID:
19594601
34.

MicroRNAs: key players in carcinogenesis and novel therapeutic targets.

Mirnezami AH, Pickard K, Zhang L, Primrose JN, Packham G.

Eur J Surg Oncol. 2009 Apr;35(4):339-47. doi: 10.1016/j.ejso.2008.06.006. Epub 2008 Jul 21. Review.

PMID:
18644693
35.

Role of the unique N-terminal domain of CtBP2 in determining the subcellular localisation of CtBP family proteins.

Bergman LM, Morris L, Darley M, Mirnezami AH, Gunatilake SC, Blaydes JP.

BMC Cell Biol. 2006 Sep 25;7:35.

36.

Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription.

Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW, Blaydes JP.

Curr Biol. 2003 Jul 15;13(14):1234-9.

Supplemental Content

Loading ...
Support Center